• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    12/12/23 12:31:12 PM ET
    $ACHV
    $ADTX
    $CADL
    $CCCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACHV alert in real time by email

    Gainers

    • C4 Therapeutics (NASDAQ:CCCC) stock increased by 100.5% to $2.37 during Tuesday's regular session. The market value of their outstanding shares is at $116.6 million.
    • Aditxt (NASDAQ:ADTX) shares rose 68.94% to $6.42. The market value of their outstanding shares is at $2.8 million.
    • Icosavax (NASDAQ:ICVX) shares rose 48.61% to $15.59. The company's market cap stands at $780.9 million.
    • Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 32.98% to $1.16. The company's market cap stands at $33.4 million.
    • IN8bio (NASDAQ:INAB) shares increased by 29.93% to $1.66. The market value of their outstanding shares is at $53.2 million.
    • PAVmed (NASDAQ:PAVM) stock rose 29.33% to $4.01. The market value of their outstanding shares is at $32.2 million.

    Losers

    • CareCloud (NASDAQ:CCLDO) stock declined by 68.4% to $4.36 during Tuesday's regular session.
    • CareCloud (NASDAQ:CCLDP) stock fell 66.43% to $5.12.
    • Achieve Life Sciences (NASDAQ:ACHV) stock fell 41.47% to $3.19. The company's market cap stands at $67.5 million.
    • Eterna Therapeutics (NASDAQ:ERNA) stock fell 23.46% to $1.2. The market value of their outstanding shares is at $6.4 million.
    • CareCloud (NASDAQ:CCLD) stock declined by 21.57% to $0.8. The market value of their outstanding shares is at $12.6 million.
    • Vapotherm (NYSE:VAPO) stock decreased by 20.01% to $1.2. The market value of their outstanding shares is at $7.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV
    $ADTX
    $CADL
    $CCCC

    CompanyDatePrice TargetRatingAnalyst
    C4 Therapeutics Inc.
    $CCCC
    12/2/2025Buy
    TD Cowen
    Achieve Life Sciences Inc.
    $ACHV
    11/25/2025$19.00Mkt Outperform
    Citizens JMP
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    C4 Therapeutics Inc.
    $CCCC
    9/17/2025$8.00Overweight
    Barclays
    C4 Therapeutics Inc.
    $CCCC
    9/15/2025$6.00Equal-Weight → Overweight
    Stephens
    C4 Therapeutics Inc.
    $CCCC
    9/4/2025$8.00Buy
    Guggenheim
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    Achieve Life Sciences Inc.
    $ACHV
    8/21/2025$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACHV
    $ADTX
    $CADL
    $CCCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    CareCloud Unveils Next-Generation MAP App at HFMA Revenue Cycle Conference

    SOMERSET, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- CareCloud, Inc. (NASDAQ:CCLD, CCLDO)) ("CareCloud" or the "Company"), a leader in healthcare technology and AI-powered solutions, today announced that the Company will attend the HFMA Revenue Cycle Conference in Arlington, Texas, where it will showcase the continued evolution of MAP App, its web-based revenue cycle benchmarking. CareCloud will also host a networking happy hour during the conference and offer a live webinar for those unable to attend in person. MAP App entered CareCloud's AI-driven technology product portfolio through the Company's acquisition of the platform from HFMA, adding a nationally recognized revenue cycle benchmar

    3/18/26 8:00:00 AM ET
    $CCLD
    Computer Software: Prepackaged Software
    Technology

    Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

    SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 4Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referenci

    3/17/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    $ADTX
    $CADL
    $CCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on C4 Therapeutics

    TD Cowen initiated coverage of C4 Therapeutics with a rating of Buy

    12/2/25 8:23:26 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citizens JMP initiated coverage on Achieve Life Sciences with a new price target

    Citizens JMP initiated coverage of Achieve Life Sciences with a rating of Mkt Outperform and set a new price target of $19.00

    11/25/25 8:38:19 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $ADTX
    $CADL
    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Business Officer Boyle Scott N was granted 200,000 shares, converted options into 25,950 shares and covered exercise/tax liability with 9,004 shares, increasing direct ownership by 177% to 298,801 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    2/18/26 5:05:18 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Mahaney Paige was granted 240,000 shares, converted options into 7,050 shares and covered exercise/tax liability with 2,446 shares, increasing direct ownership by 239% to 336,910 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    2/18/26 5:05:11 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $ADTX
    $CADL
    $CCCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    2/17/26 9:14:34 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cherington Charles bought $2,221,826 worth of shares (21,241,163 units at $0.10), increasing direct ownership by 104% to 41,659,743 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    6/11/25 8:34:12 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHV
    $ADTX
    $CADL
    $CCCC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.

    SCHEDULE 13D/A - Candel Therapeutics, Inc. (0001841387) (Subject)

    3/18/26 4:23:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Ernexa Therapeutics Inc.

    10-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

    3/13/26 5:22:06 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Aditxt, Inc. (0001726711) (Filer)

    3/13/26 8:35:24 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHV
    $ADTX
    $CADL
    $CCCC
    Leadership Updates

    Live Leadership Updates

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    CareCloud Appoints Chief Strategy Officer to Lead Enterprise AI Platform as Company Enters 2026 as Its Defining AI Year

    Strategic leadership alignment positions CareCloud to scale execution, expand margins, and accelerate AI-driven innovation across ambulatory and hospital markets SOMERSET, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (NASDAQ:CCLD, CCLDO)), ("CareCloud" or the "Company") a leader in healthcare technology and AI-powered solutions, today announced leadership promotions designed to align the organization for its next phase of growth and to position 2026 as a defining year for enterprise AI innovation across the Company's platform. Effective January 1, 2026, A. Hadi Chaudhry will serve as Chief Strategy Officer, leading CareCloud's enterprise AI vision, platform innovation, and com

    12/29/25 8:00:00 AM ET
    $CCLD
    Computer Software: Prepackaged Software
    Technology

    Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

    CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women's oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa's capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human tria

    12/2/25 8:50:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHV
    $ADTX
    $CADL
    $CCCC
    Financials

    Live finance-specific insights

    View All

    Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

    SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 4Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referenci

    3/17/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHV
    $ADTX
    $CADL
    $CCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by C4 Therapeutics Inc.

    SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 6:43:36 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care